David Lazar - 24 Nov 2025 Form 4 Insider Report for KALA BIO, Inc. (KALA)

Role: Chief Executive Officer, Director
Signature: /s/ David E. Lazar
Issuer symbol: KALA
Transactions as of: 24 Nov 2025
Net transactions value: $0
Form type: 4
Filing time: 26 Nov 2025, 15:03:05 UTC
Previous filing: 02 Dec 2025
Next filing: 22 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Lazar David E.	Chief Executive Officer, Director	44, TOWER 100, THE TOWERS, WINSTON CHURCHILL, PAITILLA, PANAMA CITY, PANAMA	/s/ David E. Lazar	26 Nov 2025	0001932843

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	KALA	Common Stock						0	24 Nov 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KALA	Series AA Convertible Preferred Stock	Award		+900,000			900,000	24 Nov 2025	Common Stock	49,500,000		Direct	F2, F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	No shares of common stock are beneficially owned.
F2	On November 24, 2025, David E. Lazar (the "Reporting Person") and KALA BIO, Inc. (the "Company") entered into a securies purchase agreement (the "Purchase Agreement") pursuant to which the Reporting Person acquired an aggregate of 900,000 shares of the Company's Series AA Convertible Non-Redeemable Preferred Stock (the "Series AA Preferred Stock") at a price of $2.00 per share, for a total purchase price of $1,800,000. Pursuant to the Purchase Agreement, the Reporting Person will also acquire, at a subsequent closing, an aggregate of 2,100,000 shares of the Company's Series AAA Convertible Non-Redeemable Preferred Stock (the "Series AAA Preferred Stock", and together with the Series AA Preferred Stock, the "Preferred Stock") at a price of $2.00 per share, for an additional purchase price of $4,200,000.
F3	Each share of Series AA Preferred Stock will be convertible into 55 shares of the Company's common stock at any time, subject to certain ownership limitations. Each share of Series AAA Preferred Stock will be convertible into 420 shares of the Company's common stock at any time, subject to certain ownership limitations. No shares of Preferred Stock will be convertible until the Company's stockholders approve a) an increase in the Company's authorized capital to enable the Company to issue all of the shares of common stock that are issuable upon the conversion of the Preferred Stock and b) the conversion of the Preferred Stock into shares of common stock in accordance with the listing rules of The Nasdaq Stock Market, LLC (the "Stockholder Approval").
F4	Following receipt by the Company of the Stockholder Approval, the shares of Series AA Preferred Stock will be convertible at the option of the Reporting Person for no additional consideration.
F5	The Series AA Preferred Stock is perpetual and therefore has no expiration date.